Iodine-refractory thyroid carcinoma.

Apar Kishor P Ganti, Ezra E W Cohen

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The management of thyroid carcinomas commonly involves thyroidectomy, radioactive iodine to ablate any thyroid remnant in patients at high risk of recurrence, and suppressive thyroid hormone replacement. However many tumors will de-differentiate and become refractory to radioactive iodine. After progressive dedifferentiation the prognosis for these patients is poor, with no curative options available as these tumors respond poorly to currently available agents. In this review, we examine the unique biology of thyroid cancer and the various intracellular pathways which are currently the subject of intensive focus. Trials evaluating the efficacy of cytotoxic chemotherapeutic agents in iodine-refractory thyroid carcinoma and current novel therapeutic approaches will be emphasized.

Original languageEnglish (US)
Pages (from-to)133-141
Number of pages9
JournalReviews on recent clinical trials
Volume1
Issue number2
DOIs
StatePublished - Jan 1 2006

Fingerprint

Thyroid Neoplasms
Iodine
Thyroidectomy
Cytotoxins
Thyroid Hormones
Neoplasms
Thyroid Gland
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Iodine-refractory thyroid carcinoma. / Ganti, Apar Kishor P; Cohen, Ezra E W.

In: Reviews on recent clinical trials, Vol. 1, No. 2, 01.01.2006, p. 133-141.

Research output: Contribution to journalReview article

Ganti, Apar Kishor P ; Cohen, Ezra E W. / Iodine-refractory thyroid carcinoma. In: Reviews on recent clinical trials. 2006 ; Vol. 1, No. 2. pp. 133-141.
@article{88a1800628cc44b498c4f9a30898bb9f,
title = "Iodine-refractory thyroid carcinoma.",
abstract = "The management of thyroid carcinomas commonly involves thyroidectomy, radioactive iodine to ablate any thyroid remnant in patients at high risk of recurrence, and suppressive thyroid hormone replacement. However many tumors will de-differentiate and become refractory to radioactive iodine. After progressive dedifferentiation the prognosis for these patients is poor, with no curative options available as these tumors respond poorly to currently available agents. In this review, we examine the unique biology of thyroid cancer and the various intracellular pathways which are currently the subject of intensive focus. Trials evaluating the efficacy of cytotoxic chemotherapeutic agents in iodine-refractory thyroid carcinoma and current novel therapeutic approaches will be emphasized.",
author = "Ganti, {Apar Kishor P} and Cohen, {Ezra E W}",
year = "2006",
month = "1",
day = "1",
doi = "10.2174/157488706776876526",
language = "English (US)",
volume = "1",
pages = "133--141",
journal = "Reviews on Recent Clinical Trials",
issn = "1574-8871",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Iodine-refractory thyroid carcinoma.

AU - Ganti, Apar Kishor P

AU - Cohen, Ezra E W

PY - 2006/1/1

Y1 - 2006/1/1

N2 - The management of thyroid carcinomas commonly involves thyroidectomy, radioactive iodine to ablate any thyroid remnant in patients at high risk of recurrence, and suppressive thyroid hormone replacement. However many tumors will de-differentiate and become refractory to radioactive iodine. After progressive dedifferentiation the prognosis for these patients is poor, with no curative options available as these tumors respond poorly to currently available agents. In this review, we examine the unique biology of thyroid cancer and the various intracellular pathways which are currently the subject of intensive focus. Trials evaluating the efficacy of cytotoxic chemotherapeutic agents in iodine-refractory thyroid carcinoma and current novel therapeutic approaches will be emphasized.

AB - The management of thyroid carcinomas commonly involves thyroidectomy, radioactive iodine to ablate any thyroid remnant in patients at high risk of recurrence, and suppressive thyroid hormone replacement. However many tumors will de-differentiate and become refractory to radioactive iodine. After progressive dedifferentiation the prognosis for these patients is poor, with no curative options available as these tumors respond poorly to currently available agents. In this review, we examine the unique biology of thyroid cancer and the various intracellular pathways which are currently the subject of intensive focus. Trials evaluating the efficacy of cytotoxic chemotherapeutic agents in iodine-refractory thyroid carcinoma and current novel therapeutic approaches will be emphasized.

UR - http://www.scopus.com/inward/record.url?scp=45549084602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549084602&partnerID=8YFLogxK

U2 - 10.2174/157488706776876526

DO - 10.2174/157488706776876526

M3 - Review article

VL - 1

SP - 133

EP - 141

JO - Reviews on Recent Clinical Trials

JF - Reviews on Recent Clinical Trials

SN - 1574-8871

IS - 2

ER -